Seguimiento de graduados de la Carrera de Médico Especialista en cardiología de la Universidad de Buenos Aires. Experiencia del Hospital Cosme Argerich / Follow-up of Specialist in Cardiology Graduates at University of Buenos Aires. Cosme Argerich Hospital Experience

RESUMEN El seguimiento de los graduados en una carrera es un indicador de la calidad educativa de la misma. Su labor profesional y académica permite evaluar los resultados de los programas instituidos a largo plazo. Objetivo: Explorar la percepción de los egresados de la Carrera de Médico Especialista (CME) en cardiología de la Universidad de Buenos Aires (UBA) sede Hospital Argerich sobre la calidad de la formación recibida durante la carrera; conocer su inserción laboral en el mundo profesional, y la realización de subespecialidades. Material y métodos: Estudio descriptivo, de corte transversal, realizado del 1° al 31 de enero de 2020. Se diseñó una encuesta de opinión autoadministrada a través de surveymonkey.com. El universo encuestado fueron 28 egresados de 7 promociones consecutivas (año de admisión 2010-2016) de la Carrera de Médico Especialista (CME) en cardiología UBA-sede Argerich. Resultados: Del total de los egresados contestaron la encuesta 25 (89,2%). La edad promedio fue 34 años, sexo masculino 14 (56%). Se realizaron preguntas para la evaluación global, valoración de la actividad científica y académica en la Sede del Hospital, al igual que la valoración del Curso Bianual de Cardiología en la Sociedad Argentina de Cardiología. Las respuestas en su mayoría fueron favorables Los egresados continúan ejerciendo la profesión en un 100%, el 76% se perfeccionó en una subespecialidad. Conclusiones: Los egresados de la CME en cardiología sede Hospital Argerich perciben que su formación ha sido muy buena o excelente y ha contribuido a su desarrollo profesional de manera esencial. Toda la información recabada genera una fuente de información para retroalimentar y optimizar la enseñanza en la institución formadora.

ABSTRACT Background: Follow-up of graduates in a career is an indicator of educational quality, and their professional and academic work allows evaluating the results of long-term instituted programs Objective: The aim of this study was to explore the perception of graduates from the postgraduate specialist course (PSC) in cardiology at University of Buenos Aires (UBA) Hospital Argerich venue on the quality of training received, how they insert in the professional world, and their engagement in subspecialties. Methods: A descriptive, cross-sectional study was carried out from January 1 to 31, 2020. A self-administered opinion survey was designed using surveymonkey.com and submitted to 28 graduates of the PSC in cardiology UBA-Hospital Argerich, corresponding to 7 consecutive promotions (2010-2016 years of admission). Results: The survey was answered by 25 graduates (89.2%). Mean age was 34 years and 14 (56%) were men. The questions explored the global assessment, the evaluation of the scientific and academic activity at the hospital venue as well as that of the Argentine Society of Cardiology Biennial Course of Cardiology. Most of the answers were favorable. All the graduates continue practicing the profession and 76% have received advanced training in a subspecialty. Conclusions: Graduates from the PSC in cardiology at Hospital Argerich perceive that their training has been very good or excellent and has been essential for their professional development. All the data collected are a source of information to provide feedback and optimize teaching in the training institution.

[In-hospital complications of acute myocardial infarction. Incidence and timing of their occurrence]. / Complicaciones intrahospitalarias del infarto agudo de miocardio. Incidencia y momento de aparición.

Although ST-segment elevation myocardial infarction (STEMI) mortality decreased with the progress of reperfusion, the incidence of hospital complications has not changed. We aimed to describe the incidence of STEMI complications in the coronary unit, the timing of their occurrence and to identify their predisposing and protective factors. This is a prospective analysis of all consecutive patients with STEMI admitted to a coronary care unit of a third level reference hospital from September 2017 to March 2020. Of the 263 STEMI, 124 developed complications (47.2%), and the most frequent was heart failure. In the multivariate analysis, preadmission cardiac arrest (CA) (OR: 9.8; CI: 1.2-81.9; p = 0.03), left ventricular ejection fraction (Fey VI) < 40% (OR: 2.3 CI: 1.3-3.9; p = 0.004) and age > 68 years (OR: 2.2; CI: 1.2-4.0; p = 0.01) were predictors of complications. Successful reperfusion (OR: 0.2 CI: 0.005-0.7; p = 0.02) and the presentation of Killip and Kimball (KK) A (OR: 0.0002 CI: 0.00001-0.003; p = < 0.00001) were protective factors. Most complications occurred on the first day (88.7%) and in all but one patient within the first 48 hours. Acute complications of STEMI occurred very frequently and the most prevalent was heart failure. KKA and successful reperfusion are low risks predictors, while 6 out of 10 patients with Fey VI < 40%, Cardiac arrest before admission or age >68 years suffered an event. Almost all complications happened within the first 48 hours.

Aunque la mortalidad del infarto de miocardio con elevación del segmento ST (IAMCEST) ha disminuido con el progreso de la reperfusión, la incidencia de sus complicaciones no ha cambiado. El objetivo del estudio es conocer la incidencia de las complicaciones hospitalarias del IAMCEST, su cronología de aparición e identificar sus predictores. Se realizó un análisis prospectivo de todos los pacientes consecutivos con IAMCEST ingresados en una unidad coronaria de un Hospital público de la ciudad de Buenos Aires desde septiembre de 2017 a marzo de 2020. De 263 pacientes con IAMCEST, el 47.2% (124) presentó complicaciones siendo la insuficiencia cardíaca (IC) la más frecuente. El paro cardiaco previo al ingreso (PCR) (OR: 9.8; IC: 1.2-81.9; p = 0.03), la fracción de eyección del ventrículo izquierdo (Fey VI) < del 40% (OR: 2.3 IC: 1.3-3.9; p = 0.004) y la edad > de 68 años (OR: 2.2; IC: 1.2-4,0; p = 0.01) fueron sus predictores. La reperfusión exitosa (OR: 0.2 IC: 0.005-0.7; p = 0.02) y la presentación de Killip y Kimball (KK) A (OR: 0.0002 IC: 0.00001-0.003; p = < 0.00001) fueron factores protectores. El 88.7% (110) se complicó el primer día de internación y todos (con excepción de un solo paciente) dentro de las 48 horas. Las complicaciones post IAMCEST son muy frecuentes, suceden dentro de los primeros dos días de internación y la IC es la más prevalente. Detectamos un grupo con menor riesgo que podría tener una internación abreviada de solo 48 horas.

Complicaciones intrahospitalarias del infarto agudo de miocardio. Incidencia y momento de aparición / In-hospital complications of acute myocardial infarction. Incidence and timing of their occurrence

Resumen Aunque la mortalidad del infarto de miocardio con elevación del segmento ST (IAMCEST) ha disminuido con el progreso de la reperfusión, la incidencia de sus complicaciones no ha cambiado. El objetivo del estudio es conocer la incidencia de las complicaciones hospitalarias del IAMCEST, su cronología de aparición e identificar sus predictores. Se realizó un análisis prospectivo de todos los pacientes consecutivos con IAMCEST ingresados en una unidad coronaria de un Hospital público de la ciudad de Buenos Aires desde septiembre de 2017 a marzo de 2020. De 263 pacientes con IAMCEST, el 47.2% (124) presentó complicacio nes siendo la insuficiencia cardíaca (IC) la más frecuente. El paro cardiaco previo al ingreso (PCR) (OR: 9.8; IC: 1.2-81.9; p = 0.03), la fracción de eyección del ventrículo izquierdo (Fey VI) < del 40% (OR: 2.3 IC: 1.3-3.9; p = 0.004) y la edad > de 68 años (OR: 2.2; IC: 1.2-4,0; p = 0.01) fueron sus predictores. La reperfusión exitosa (OR: 0.2 IC: 0.005-0.7; p = 0.02) y la presentación de Killip y Kimball (KK) A (OR: 0.0002 IC: 0.00001-0.003; p = < 0.00001) fueron factores protectores. El 88.7% (110) se complicó el primer día de internación y todos (con excepción de un solo paciente) dentro de las 48 horas. Las complicaciones post IAMCEST son muy frecuentes, suceden dentro de los primeros dos días de internación y la IC es la más prevalente. Detectamos un grupo con menor riesgo que podría tener una internación abreviada de solo 48 horas.

Abstract Although ST-segment elevation myocardial infarction (STEMI) mortality decreased with the progress of reperfusion, the incidence of hospital complications has not changed. We aimed to describe the incidence of STEMI complications in the coronary unit, the timing of their occurrence and to identify their predis posing and protective factors. This is a prospective analysis of all consecutive patients with STEMI admitted to a coronary care unit of a third level reference hospital from September 2017 to March 2020. Of the 263 STEMI, 124 developed complications (47.2%), and the most frequent was heart failure. In the multivariate analysis, pre-admission cardiac arrest (CA) (OR: 9.8; CI: 1.2-81.9; p = 0.03), left ventricular ejection fraction (Fey VI) < 40% (OR: 2.3 CI: 1.3-3.9; p = 0.004) and age > 68 years (OR: 2.2; CI: 1.2-4.0; p = 0.01) were predictors of complica tions. Successful reperfusion (OR: 0.2 CI: 0.005-0.7; p = 0.02) and the presentation of Killip and Kimball (KK) A (OR: 0.0002 CI: 0.00001-0.003; p = < 0.00001) were protective factors. Most complications occurred on the first day (88.7%) and in all but one patient within the first 48 hours. Acute complications of STEMI occurred very frequently and the most prevalent was heart failure. KKA and successful reperfusion are low risks predictors, while 6 out of 10 patients with Fey VI < 40%, Cardiac arrest before admission or age >68 years suffered an event. Almost all complications happened within the first 48 hours.

Impact of a prolonged COVID-19 lockdown on patterns of admission, mortality and performance indicators in a cardiovascular intensive care unit.

BACKGROUND: The effects of an early and prolonged lockdown during the coronavirus disease 2019 (COVID-19) pandemic on cardiovascular intensive care units (CICUs) are not well established. OBJECTIVES: This study analyses patterns of admission, mortality and performance indicators in a CICU before and during the Argentine lockdown in the COVID-19 pandemic. METHODS: This is a retrospective observational cross-sectional study of all consecutive patients aged 18 years or more admitted to the cardiac intensive care unit at a high-volume reference hospital in Buenos Aires, Argentina, comparing hospitalization rates, primary causes of admission, inpatient utilization indicators, pharmacy supplies' expenditures and in-hospital mortality between 5 March and 31 July 2020, with two corresponding control periods in 2019 and 2018. RESULTS: We included 722 female patients [mean age of 61.6 (SD 15.5) years; 237 (32.8%)]. Overall hospitalizations dropped 53.2% (95%CI: 45.3, 61.0%), from 295.5 patients/year over the periods 2018/2019 to 137 patients in 2020. Cardiovascular disease-related admissions dropped 59.9%, while admission for non-cardiac causes doubled its prevalence from 9.6% over the periods 2018/2019 to 22.6% in the study period (P < 0.001).In the period 2020, the bed occupancy rate fell from 82.2% to 77.4%, and the bed turnover rate dropped 50% from 7.88 to 3.91 monthly discharges/bed. The average length of stay doubled from 3.26 to 6.75 days, and the turnover interval increased from 3.8 to 8.39 days in 2020.Pharmacy supplies' expenditures per discharge increased 134% along with a rise in antibiotics usage from 6.5 to 11.4 vials/ampoules per discharge (P < 0.02).Overall mortality increased from 7% (n = 41) to 13.9% (n = 19) (P = 0.008) at the expense of non-cardiac-related admissions (3.6-19.4%, P = 0.01). CONCLUSIONS: This study found a significant reduction in overall and cardiovascular disease-related causes of admission to the cardiac intensive care unit, worse performance indicators and increased in-hospital mortality along the first 5 months of the early and long-lasting COVID-19 lockdown in Argentina. These results highlight the need to foster public awareness concerning the risks of avoiding hospital attendance. Moreover, health systems should follow strict screening protocols to prevent potential biases in the admission of patients with critical conditions unrelated to the COVID-19 pandemic.

Severe hyperkalaemia due to a potential drug-drug interaction between eplerenone and antiretrovirals in a HIV-positive patient after a myocardial infarction.

We present a case of a 48-year-old white HIV-1 positive man who presented an acute myocardial infarction. The patient was on ART for the last ten years with emtricitabine/tenofovir and ritonavir-boosted fosamprenavir. Eplerenone 25 mg/day was also initiated due to a left ventricular dysfunction. A week after discharge a routine laboratory examination revealed severe hyperkalaemia. Due to suspicion of a potential drug-drug interaction, both eplerenone and ARVs were interrupted. Despite daily treatment for hyperkalaemia, serum potassium levels normalized after two weeks. Eplerenone is metabolized by the hepatic P450 cytochrome isoenzyme CYP3A4; therefore, concomitant administration with CYP3A4 inhibitors, like ritonavir, may increase plasma levels of eplerenone and, therefore, the risk of side effects, mainly hyperkalaemia. Based on this case, it is important to alert the medical community of this possible life-threatening drug-drug interaction between eplerenone and ritonavir-boosted protease inhibitor.

[Cilostazol and sick sinus syndrome]. / Efecto del cilostazol en la enfermedad del nodo sinusal.

Here we present the case of a 60-year-old patient with sinus node disease (NSS), symptomatic with dizziness and angor. The electrocardiogram showed episodes of sinus pauses with nodal escapes. During hospitalization, pending the placement of a definitive pacemaker, cilostazol (100 mg every 12 hours orally) was indicated, observing an increase in heart rate 48 hours after starting the medication, and the disappearance of sinus pauses in the 24 hours Holter. Our objective has been to show that cilostazol can be useful in patients with SNN, although long-term chronotropic effects of this treatment has yet to be evaluated.

Se presenta el caso de una paciente de 60 años con enfermedad del nodo sinusal (ENS), sintomática con mareos y ángor, con electrocardiograma que evidenciaba episodios de pausas sinusales con escapes nodales. Durante la internación, a la espera de colocación de marcapaso definitivo, se indicó cilostazol (100 mg cada 12 h vía oral), observando a las 48 horas del inicio un incremento en la frecuencia cardíaca y la desaparición de las pausas sinusales en Holter de 24 horas. Nue stro objetivo ha sido demostrar que el cilostazol puede ser útil en pacientes con ENS, aunque es necesario evaluar los efectos cronotrópicos a largo plazo de este tratamiento.

Efecto del cilostazol en la enfermedad del nodo sinusal / Cilostazol and sick sinus syndrome

Resumen Se presenta el caso de una paciente de 60 años con enfermedad del nodo sinusal (ENS), sintomática con mareos y ángor, con electrocardiograma que evidenciaba episodios de pausas sinusales con escapes nodales. Durante la internación, a la espera de colocación de marcapaso definitivo, se indicó cilostazol (100 mg cada 12 h vía oral), observando a las 48 horas del inicio un incremento en la frecuencia cardíaca y la desaparición de las pausas sinusales en Holter de 24 horas. Nuestro objetivo ha sido demostrar que el cilostazol puede ser útil en pacientes con ENS, aunque es necesario evaluar los efectos cronotrópicos a largo plazo de este tratamiento.

Abstract Here we present the case of a 60-year-old patient with sinus node disease (NSS), symptomatic with dizziness and angor. The electrocardiogram showed episodes of sinus pauses with nodal escapes. During hospitalization, pending the placement of a definitive pacemaker, cilostazol (100 mg every 12 hours orally) was indicated, observing an increase in heart rate 48 hours after starting the medication, and the disappearance of sinus pauses in the 24 hours Holter. Our objective has been to show that cilostazol can be useful in patients with SNN, although long-term chronotropic effects of this treatment has yet to be evaluated.